Infectious disease
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
As Moderna moves forward with its mRNA vaccine candidate for COVID-19, the U.S. federal government is helping accelerate the potential medication with a $483 million infusion from the Biomedical Advanced Research and Development Authority.
Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease.
Although not official and largely anecdotal, there are early signs that Gilead’s experimental antiviral drug, remdesivir, is effective in treating COVID-19.
The company suggests its approach can actually help eliminate the virus from an already-infected host, while also bolstering the immune response.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018.
The two companies will evaluate a smartphone-based self-testing solution for COVID-19, using Luminostics’ innovative technology and Sanofi’s clinical research abilities.
The Mammoth DETECTR assay was validated in less than two weeks and can deliver results in less than 45 minutes.
In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic.
PRESS RELEASES